報價延遲最少15分鐘:2025/09/04 04:01 EDT
盤前時段
|
||||
|
-- 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.59
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-6.50/-0.51
|
|
企業價值
27.16M
|
| 資產負債 |
|
每股賬面淨值
0.99
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
3.34M
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/04 04:01 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options. |
